The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis

Journal of Clinical Lipidology

Volumn 9, Issue 4, 2015, Pages 498-510

  Wyler Von Ballmoos, Moritz C ^a   Haring, Bernhard ^b   Sacks, Frank M ^c  

^a FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Atherosclerosis; Cardiovascular risk; Epidemiology; Lipoprotein

Indexed keywords

APOLIPOPROTEIN C3; HIGH DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ANGINA PECTORIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; GLUCOSE METABOLISM; HUMAN; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; BLOOD; HYPERTRIGLYCERIDEMIA; META ANALYSIS; PATHOLOGY;

APOLIPOPROTEIN C-III; CARDIOVASCULAR DISEASES; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; RISK FACTORS; TRIGLYCERIDES;

EID: 84938070383     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2015.05.002     Document Type: Article

References (46)

1. E. Sehayek, and S. Eisenberg Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway J Biol Chem 266 1991 18259 18267
2. E.E. Windler, P.T. Kovanen, Y.S. Chao, M.S. Brown, R.J. Havel, and J.L. Goldstein The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E J Biol Chem 255 1980 10464 10471
3. K. Aalto-Setala, E.A. Fisher, X. Chen, and et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles J Clin Invest 90 1992 1889 1900
4. K. Aalto-Setala, P.H. Weinstock, C.L. Bisgaier, L. Wu, J.D. Smith, and J.L. Breslow Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice J Lipid Res 37 1996 1802 1811
5. H.V. de Silva, S.J. Lauer, J. Wang, and et al. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E J Biol Chem 269 1994 2324 2335
6. C. Zheng, C. Khoo, J. Furtado, and F.M. Sacks Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype Circulation 121 2010 1722 1734
7. C. Zheng, C. Khoo, K. Ikewaki, and F.M. Sacks Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions J Lipid Res 48 2007 1190 1203
8. C.O. Mendivil, C. Zheng, J. Furtado, J. Lel, and F.M. Sacks Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins Arterioscler Thromb Vasc Biol 30 2010 239 245
9. C.S. Wang, W.J. McConathy, H.U. Kloer, and P. Alaupovic Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III J Clin Invest 75 1985 384 390
10. W.V. Brown, and M.L. Baginsky Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein Biochem Biophys Res Commun 46 1972 375 382
11. M. Sundaram, S. Zhong, M. Bou Khalil, and et al. Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions J Lipid Res 51 2010 150 161
12. J.S. Cohn, B.W. Patterson, K.D. Uffelman, J. Davignon, and G. Steiner Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity J Clin Endocrinol Metab 89 2004 3949 3955
13. R. Batal, M. Tremblay, P.H. Barrett, and et al. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects J Lipid Res 41 2000 706 718
14. T. Ebara, R. Ramakrishnan, G. Steiner, and N.S. Shachter Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E J Clin Invest 99 1997 2672 2681
15. H.N. Ginsberg, N.A. Le, I.J. Goldberg, and et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo J Clin Invest 78 1986 1287 1295
16. A. Kawakami, M. Aikawa, P. Alcaide, F.W. Luscinskas, P. Libby, and F.M. Sacks Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells Circulation 114 2006 681 687
17. A. Kawakami, M. Aikawa, P. Libby, P. Alcaide, F.W. Luscinskas, and F.M. Sacks Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells Circulation 113 2006 691 700
18. A. Hiukka, M. Stahlman, C. Pettersson, and et al. ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan Diabetes 58 2009 2018 2026
19. S.J. Lee, H. Campos, L.A. Moye, and F.M. Sacks LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients Arterioscler Thromb Vasc Biol 23 2003 853 858
20. F.M. Sacks, P. Alaupovic, L.A. Moye, and et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial Circulation 102 2000 1886 1892
21. C.O. Mendivil, E.B. Rimm, J. Furtado, S.E. Chiuve, and F.M. Sacks Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease Circulation 124 2011 2065 2072
22. O. Olivieri, N. Martinelli, D. Girelli, and et al. Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation J Thromb Haemost 8 2010 463 471
23. A. Onat, G. Hergenc, V. Sansoy, and et al. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders Atherosclerosis 168 2003 81 89
24. P.G. Scheffer, T. Teerlink, J.M. Dekker, and et al. Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn Study Clin Chem 54 2008 1325 1330
25. Y. Gerber, U. Goldbourt, S. Segev, and D. Harats Indices related to apo CII and CIII serum concentrations and coronary heart disease: a case-control study Prev Med 37 2003 18 22
26. O. Olivieri, A. Bassi, C. Stranieri, and et al. Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease J Lipid Res 44 2003 2374 2381
27. T.I. Pollin, C.M. Damcott, H. Shen, and et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection Science 322 2008 1702 1705
28. R.A. Hegele Small genetic effects in complex diseases: a review of regulatory sequence variants in dyslipoproteinemia and atherosclerosis Clin Biochem 30 1997 183 188
29. R.A. Hegele, P.W. Connelly, A.J. Hanley, F. Sun, S.B. Harris, and B. Zinman Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins Arterioscler Thromb Vasc Biol 17 1997 2753 2758
30. P. Lahiry, M.R. Ban, R.L. Pollex, and et al. Common variants APOC3, APOA5, APOE and PON1 are associated with variation in plasma lipoprotein traits in Greenlanders Int J Circumpolar Health 66 2007 390 400
31. R.L. Pollex, M.R. Ban, T.K. Young, and et al. Association between the -455T>C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample BMC Med Genet 8 2007 80
32. M.K. Jensen, E.B. Rimm, J.D. Furtado, and F.M. Sacks Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease J Am Heart Assoc 1 2012
33. G. Roselli della Rovere, A. Lapolla, G. Sartore, and et al. Plasma lipoproteins, apoproteins and cardiovascular disease in type 2 diabetic patients. A nine-year follow-up study Nutr Metab Cardiovasc Dis 13 2003 46 51
34. S.A. Wiseman, J.T. Powell, N. Barber, S.E. Humphries, and R.M. Greenhalgh Influence of apolipoproteins on the anatomical distribution of arterial disease Atherosclerosis 89 1991 231 237
35. G. Luc, C. Fievet, D. Arveiler, and et al. Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Temoins sur 'Infarctus du Myocarde J Lipid Res 37 1996 508 517
36. D.F. Stroup, J.A. Berlin, S.C. Morton, and et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group JAMA 283 2000 2008 2012
37. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement J Clin Epidemiol 62 2009 1006 1012
38. S. Greenland, and M.P. Longnecker Methods for trend estimation from summarized dose-response data, with applications to meta-analysis Am J Epidemiol 135 1992 1301 1309
39. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
40. J.P. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat Med 21 2002 1539 1558
41. J.J. Genest Jr., J.M. Bard, J.C. Fruchart, J.M. Ordovas, P.F. Wilson, and E.J. Schaefer Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease Atherosclerosis 90 1991 149 157
42. J. Crosby, G.M. Peloso, P.L. Auer, and et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease N Engl J Med 371 2014 22 31
43. E.M. Ooi, P.H. Barrett, D.C. Chan, and G.F. Watts Apolipoprotein C-III: understanding an emerging cardiovascular risk factor Clin Sci (Lond) 114 2008 611 624
44. D.C. Chan, M.M. Chen, E.M. Ooi, and G.F. Watts An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? Int J Clin Pract 62 2008 799 809
45. C. Zheng Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease Curr Opin Lipidol 25 2014 35 39
46. J.D. Furtado, H. Campos, A.E. Sumner, L.J. Appel, V.J. Carey, and F.M. Sacks Dietary interventions that lower lipoproteins containing apolipoprotein C-III are more effective in whites than in blacks: results of the OmniHeart trial Am J Clin Nutr 92 2010 714 722